A new study presented at ENDO 2024 has found that GLP-1 drugs like Ozempic and Wegovy, specifically semaglutide, may influence taste sensitivity and the way the brain responds to sweet foods. The study, led by Mojca Jensterle Sever, PhD, from the University Medical Centre in Ljubljana, Slovenia, examined how semaglutide affects taste perception and gene expression in the tongue related to taste perception.
Semaglutide, also known as Ozempic and Wegovy, is a GLP-1 agonist used initially as a type 2 diabetes medication. It has shown promise in reducing appetite and promoting weight loss, making it popular for those struggling with obesity. The drug mimics hormones that signal fullness to the brain, leading to decreased food intake and weight loss.
The recent study involved 30 women with obesity who took semaglutide or a placebo for 16 weeks. The participants underwent tests to measure taste sensitivity, gene expression in the tongue, and brain responses to sweet tastes. The results showed that those taking semaglutide were more sensitive to tastes than those taking the placebo.
It is important to note that this study was conducted on a small group of people in a lab setting, so the results may not reflect everyday experiences. While semaglutide has shown impressive weight loss results, it is not suitable for everyone and should only be used under the supervision of a doctor as part of a comprehensive weight loss program.
Semaglutide may alter how individuals perceive sweet tastes, which could aid in weight loss efforts. However, the drug is not without its drawbacks, including potential side effects and the need for lifelong use to maintain weight loss. Ultimately, semaglutide should be used cautiously and as part of a holistic approach to weight management.